ValGenesis, a leader in digital validation lifecycle management backed by Morgan Stanley Expansion Capital, has secured up to $16 million in strategic financing from the Innovation Banking Group at Bridge Bank. This funding will aid ValGenesis’ global expansion and accelerate innovation in artificial intelligence-powered validation solutions.
The company recently launched an AI-assisted validation program and is known for digitizing and automating validation processes for leading pharmaceutical, biotech, and medical device organizations.
And ValGenesis also introduced ValGenesis Smart GxP, the first AI-enabled platform designed to unify validation and process lifecycle management in life sciences organizations.
How the funding will be used: The new funds will also support strategic hiring, regional partner expansion, and customer success initiatives across North America, Europe, and Asia-Pacific, enabling ValGenesis to meet the surging demand for digital validation solutions in regulated industries.
KEY QUOTES:
“We believe this financing reflects the strong confidence that Bridge Bank and Morgan Stanley Expansion Capital have in our vision, innovation, and execution. Our AI-assisted validation platform, backed by a growing number of issued patents, is transforming how life sciences companies manage compliance and accelerate time to market. This capital allows us to rapidly scale our AI offerings and deepen our global presence.”
Dr. Siva Samy, CEO and Chief Product Strategist at ValGenesis
“Bridge Bank is honored to serve as the banking partner for ValGenesis, an innovation-driven company that is leading the way in digitalizing validation in life sciences. We are confident that our support will enable ValGenesis to accelerate its growth trajectory and enhance its market presence while continuing to provide exceptional value to its customers.”
Peter Haman, market director, in Bridge Bank’s Innovation Banking Group
“ValGenesis has consistently delivered impressive double-digit growth year over year and carved out clear market leadership in bringing innovative digital validation solutions to life sciences. We are confident that this new financing positions the company to accelerate its global expansion, deepen product innovation, and redefine industry best practices.”
Melissa Daniels, Managing Director, Morgan Stanley Expansion Capital
